about
Novel chimeric somatostatin analogs: facts and perspectives.The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.The role of somatostatin and dopamine D2 receptors in endocrine tumors.Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.Somatostatin receptor ligands in the treatment of acromegaly.Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.Regulation of prostate cancer cell proliferation by somatostatin receptor activation.Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.Hormone receptors analysis in idiopathic progressive subglottic stenosis.Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors.Does pasireotide directly modulate skeletal muscle metabolism?In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expressionIn vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphyImmunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegalyEpidemiology of acromegaly in Italy: analysis from a large longitudinal primary care databaseAggressive and Malignant ProlactinomasSomatostatin receptor pathophysiology in the neuroendocrine systemCurrent perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegalyBiological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine NeoplasmsDipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patientsSodium Intake and Target Organ Damage in Hypertension-An Update about the Role of a Real VillainCell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cellsOctreotide-Resistant Acromegaly: Challenges and SolutionsSomatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies
P50
Q36782654-CD5DD80D-1CAE-4B6D-A337-D1362C5C4D0AQ37367697-51F6349B-8B27-4D81-A1C2-5ED27DD4F99BQ37786917-22DFA53D-0C7C-4E97-8075-0CA2DB7D64B3Q37963842-E99EF6A9-C7AE-4022-8797-8FA736EB3559Q38284921-26D9E6F3-EE38-459B-87F9-26545605943DQ38306336-D5AA38B8-8677-469A-ADCC-59CDDDEB86CBQ39065274-BF70FECA-8B7A-4BAE-8552-8BC1FDA598C3Q39125449-4996EA6B-2B6B-48C7-B584-0D9A3C270F5AQ39650818-56389F6C-5835-41F0-9C4C-830294772537Q39771837-18A84CF4-EB29-4D7E-B3CE-25CD429D23CEQ40931422-79971605-034E-4D01-8D62-B014BF6EFDF3Q41103332-0B10B2CC-0B8B-4CE6-9978-4B2C0C5169D0Q44896068-CD10AC05-3931-4332-BE4D-E37A072AA624Q45775011-47905634-6F48-4A65-9FDA-12E08128F1A6Q47616584-4AB42DEC-DEB3-4EDC-A955-F035D8FFCF07Q48116589-F2701A3A-2B2A-4B2F-9FE6-DF8AB3810775Q48132665-CD7DE6B3-2E51-49BF-9ECB-7E8D75F8CF90Q48307756-BBC1276A-19B9-44C4-ACF1-C0C529001259Q51092208-850C87BB-0757-4EA0-9359-B45F743E662FQ53796807-447825C8-653F-4545-BCB6-F03A5BA05B9EQ54353594-810AA8B0-F84C-495E-BD20-C43AE7E8F4CBQ57765048-48C3DCD4-993B-475D-AF2F-41A88547C952Q57810491-AD3D6E80-6A61-4295-AE66-99C3AEC5C8A0Q61952374-0F381BF3-A73C-470C-9B42-19A42C866816Q84566993-702DC99A-32E1-4351-9359-2FB003CB7086Q85336883-666DA227-BF2F-47EC-97A4-A58CA9AFDBA4Q88802580-3A92670D-BFF6-44AB-A5AB-9B78CEF6999EQ91201102-510E8639-072C-4548-B9EB-2C9C2585CA65Q91423955-7D61F3CE-AAAF-4CD4-A48D-781CEEDE9CBAQ92162405-71068860-5092-4833-A548-98A2CF47001FQ92619771-4E7897BD-322A-4679-9102-9C82EBF8BA7CQ93040691-8CF15A57-C591-471E-AE1B-1D9820CBFF6DQ93185132-9753E7AF-BE8D-458C-98D9-39802332AF3CQ93358311-FB3F92E3-C328-4A36-B2A6-55AD54633E25Q95641980-1A40FE8F-4950-4A5A-8812-FE3543713A0BQ96583477-82C0C36C-8795-47EF-AE5F-E9D7DF618543
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Federico Gatto
@ast
Federico Gatto
@en
Federico Gatto
@es
Federico Gatto
@nl
Federico Gatto
@sl
type
label
Federico Gatto
@ast
Federico Gatto
@en
Federico Gatto
@es
Federico Gatto
@nl
Federico Gatto
@sl
prefLabel
Federico Gatto
@ast
Federico Gatto
@en
Federico Gatto
@es
Federico Gatto
@nl
Federico Gatto
@sl
P106
P1153
23472550500
P21
P31
P496
0000-0002-5062-9208